The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Monday Deal Review: May 25, 2009

bignickel1This week’s deal review has a couple of new placements, a couple of new plants, a very interesting claim asserted in Boston, and many, many updates on deals we have previously covered.  Check out the full review  

Most interesting use of a “Most-Favoured Nations” clause:

QLT Inc. (NASDAQ: QLTI; TSX: QLT), having faced a jury trial that awarded the Massachusetts Eye and Ear Infirmary a 3.01% royalty on Visudyne, is now facing a claim from Massachusetts General Hospital.  Mass Gen has an MFN clause in its license with QLT, and is claiming that it too is entitled to a 3.01% royalty.  QLT got most of the claims dismissed, but one was allowed to proceed.

Securities:

New Physical Facilities:

Updates on previous deals:

Bookmark and Share

About these ads

4 responses to “Monday Deal Review: May 25, 2009

  1. Pingback: Monday Deal Review: June 1, 2009 « The Cross-Border Biotech Blog

  2. Pingback: Monday Deal Review: June 22, 2009 « The Cross-Border Biotech Blog

  3. Pingback: Monday Deal Review: August 17, 2009 « The Cross-Border Biotech Blog

  4. Pingback: Monday Biotech Deal Review: September 14, 2009 « The Cross-Border Biotech Blog

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 129 other followers